Oxford Biomedica plc (LON:OXB – Get Free Report) hit a new 52-week low on Friday . The stock traded as low as GBX 198.20 ($2.45) and last traded at GBX 199.40 ($2.46), with a volume of 165656 shares. The stock had previously closed at GBX 211 ($2.60).
Analysts Set New Price Targets
Separately, Liberum Capital decreased their target price on Oxford Biomedica from GBX 350 ($4.32) to GBX 310 ($3.83) and set a “hold” rating for the company in a report on Tuesday, September 26th.
Oxford Biomedica Price Performance
Insider Buying and Selling
In other news, insider Dame Kay Davies bought 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 26th. The stock was purchased at an average price of GBX 291 ($3.59) per share, with a total value of £2,910 ($3,592.15). In related news, insider Roch Doliveux purchased 36,130 shares of the firm’s stock in a transaction on Wednesday, September 20th. The stock was bought at an average cost of GBX 274 ($3.38) per share, with a total value of £98,996.20 ($122,202.44). Also, insider Dame Kay Davies purchased 1,000 shares of the firm’s stock in a transaction on Tuesday, September 26th. The stock was bought at an average cost of GBX 291 ($3.59) per share, with a total value of £2,910 ($3,592.15). Corporate insiders own 8.68% of the company’s stock.
Oxford Biomedica Company Profile
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.
- Five stocks we like better than Oxford Biomedica
- What is the Australian Securities Exchange (ASX)
- MarketBeat Week in Review – 11/6 – 11/10
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Data giants MongoDB and Snowflake just got upgraded
- How to Invest in Small Cap Stocks
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.